Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol.

Literature DB >> 345994

Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol.

Abstract

Serum analysis carried out about 7 days before menstruation in 33 patients with mastodynia and 20 controls confirmed that progesterone is frequently decreased and prolactinaemia increased in the patients with mastodynia compared with controls of the same age. In a double blind trial, administration of Lynestrenol to 47 patients with mastodynia (each of whom was given 10 mg per day from the 10th to the 24th day of the cycle) resulted in a significant improvement of this condition in 80% of the treated cases. The therapeutic failures may be explained by anomalies in the secretion of prolactin, and may possibly be linked to individual sensitivity factors.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1978 PMID： 345994 DOI： 10.1007/bf00672829

Source DB: PubMed Journal: Arch Gynakol ISSN： 0003-9128

12 in total

7. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease.

Authors: C Nappi; P Affinito; C Di Carlo; G Esposito; U Montemagno
Journal: J Endocrinol Invest Date: 1992-12 Impact factor: 4.256

7 in total

Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol.

1. [The place of preoperative examinations in the diagnosis and treatment of breast cancer in its early stages].

2. Cystic disease of the breast: human and experimental.

3. Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone.

4. The inhibition by progesterone of uterine epithelial proliferation in the mouse.

5. Relation of prolactin and estrogen to mammary tumorigenesis in the rat.

6. Solid-phase radioimmunoassay of estradiol-17 beta.

7. [Dosage of prolactin in normal and pathological subjects (author's transl)].

8. Serum-prolatic in women with premenstrual syndrome.

9. [Hormonal function of the ovarian corpus luteum during benign mammary diseases].

10. Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154).

1. The effect of danazol on the pituitary function, thyroid function, and mastodynia.

2. PRL, TSH, and thyroid hormones in benign breast diseases.

3. Effects of synthetic gestagens on serum prolactin and growth hormone secretion in amenorrheic patients.

4. A randomised controlled trial of medroxyprogesterone acetate in mastalgia.

5. A systematic review of current understanding and management of mastalgia.

Review 6. Management of breast pain and nodularity.

7. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease.